Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
7.64% $0.906
America/New_York / 28 mar 2024 @ 11:31
FUNDAMENTALS | |
---|---|
MarketCap: | 82.10 mill |
EPS: | -0.390 |
P/E: | -2.32 |
Earnings Date: | Mar 27, 2024 |
SharesOutstanding: | 90.62 mill |
Avg Daily Volume: | 0.526 mill |
RATING 2024-03-27 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.32 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.39x |
Company: PE -2.32 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.881 - 0.959 ( +/- 4.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Ward Shane | Buy | 120 000 | Common Stock |
2024-03-15 | Ward Shane | Buy | 250 000 | Employee Stock Option (right to buy) |
2024-03-15 | Shah Preetam | Buy | 108 750 | Common Stock |
2024-03-15 | Shah Preetam | Buy | 217 500 | Employee Stock Option (right to buy) |
2024-03-15 | Tari Leslie | Buy | 111 250 | Common Stock |
INSIDER POWER |
---|
89.26 |
Last 100 transactions |
Buy: 7 175 633 | Sell: 576 273 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.906 (7.64% ) |
Volume | 0.942 mill |
Avg. Vol. | 0.526 mill |
% of Avg. Vol | 179.29 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.